Watson Pharmaceuticals has expanded its commercial presence in Latin America by gaining a minority holding in speciality pharmaceutical firm Moksha8.

With the $30m investment, Watson will fund a targeted $50m Series C round of financing that will enable Moksha8 to add an additional 12 drugs to its portfolio.

An additional investment of $20m will be made should the Sao Paulo-based company acquire additional drugs already identified.

Although specific drugs have yet to be disclosed, Moksha8 chief executive Simba Gill confirmed the inclusion of CNS products, expanding on their existing CNS medication Rivotril.